We found evidence of ZIKV infection in amniotic epithelial cells and in fetal mesenchymal cells with affinity for perichondrium. Our observation indicates that ZIKV replicates in pluripotent (amniotic stem) cells involved in early-stage embryo development. The observation of prolonged viremia until day 21 in the patient is in concordance with the findings of Driggers et al.3 and provides further data for consideration in the ongoing development of testing algorithms in pregnant women. These algorithms are currently based on the assumption that ZIKV viremia can be detected only up to 7 days.

Annemiek A. van der Eijk, M.D., Ph.D.
Erasmus Medical Center
Rotterdam, the Netherlands
a.vandereijk@erasusmc.nl
Perry J. van Genderen, M.D., Ph.D.
Harbour Hospital
Rotterdam, the Netherlands
Marion P.G. Koopmans, D.V.M., Ph.D.
Erasmus Medical Center
Rotterdam, the Netherlands
and Others

Drs. van der Eijk and van Genderen contributed equally to this letter.
A complete list of authors is available with the full text of this letter at NEJM.org.
Supported by the Horizon 2020 research and innovation program of the European Union (grant agreement no. 643476) and by the European Virus Archive Goes Global project, which received a grant (653316) from the European Union Horizon 2020 Framework Program for Research and Innovation.
Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on July 27, 2016, at NEJM.org.


DOI: 10.1056/NEJMc1605898

Cheyne–Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea

TO THE EDITOR: Dyspnea is a common side effect of the P2Y12-receptor antagonist ticagrelor in patients who receive this drug after an acute coronary syndrome.1,2 Symptoms develop in a dose-dependent fashion and usually disappear on discontinuation of ticagrelor and with reductions in plasma levels of the drug.1,2 The mechanism of this side effect, which is unrelated to negative effects on cardiac and pulmonary function, is unknown.2

Here we describe the case of a patient (Patient 1) who was hospitalized for non–ST-segment elevation myocardial infarction. After the patient underwent complete revascularization for three-vessel coronary artery disease, double antiplatelet therapy with aspirin and ticagrelor was initiated. Within a few hours after the administration of ticagrelor, the patient began to report dyspnea, particularly at night and in the supine position, despite normal systolic and diastolic left ventricular function and normal pulmonary function. The results of the arterial blood gas analysis were normal, as were outcomes of pulmonary function as assessed by spirometry, which was performed in conformity with the American Thoracic Society–European Respiratory Society standards and included measures of slow vital capacity, forced vital capacity, and forced expiratory volume in 1 second; static lung volumes; and the diffusing capacity of the lung for carbon monoxide.

One month later, during a visit for persisting dyspnea, the patient was observed to have an abnormal pattern of periodic breathing, with alternating apneas and hyperventilation. Thus, 24-hour cardiorespiratory monitoring was performed. As shown in Figure 1A (top), this monitoring revealed the presence of Cheyne–Stokes respiration (central apnea and hyperventilation), which occurred during both the night and the day. The rebreathing technique (i.e., a breathing circuit in which exhaled air is inhaled with or without absorption of carbon dioxide or oxygen) also showed increased chemosensitivity to hypercapnia (Fig. 1A, middle) and normal chemosensitivity to hypoxia.3
Immediately after the patient discontinued ticagrelor and switched to clopidogrel, the dyspnea attenuated and then disappeared. Serial evaluations of the patient’s breathing pattern and chemosensitivity performed at 1 week and at 1 month after discontinuation of ticagrelor showed a progressive reduction, to normal values, of both the apnea–hypopnea index (AHI, the number of occurrences of apnea or hypopnea per hour) (Fig. 1B, top, and 1C, top) and chemosensitivity to hypercapnia (Fig. 1B, middle, and 1C, middle).

The same respiratory pattern was confirmed in three other patients who had normal cardiovascular function and who were screened for Cheyne–Stokes respiration 1 month after an acute coronary syndrome. In Patient 2, the diurnal AHI was 28 and the nocturnal AHI was 48. In Patient 3, the diurnal AHI was 41 and the nocturnal AHI 74, and in Patient 4, the diurnal AHI was 30 and the nocturnal AHI 58. In these three patients, ticagrelor was continued on the basis of a clinical decision, and in two patients, the follow-up confirmed the persistence of Cheyne–Stokes respiration. In Patient 2, the diurnal AHI after 1 week was 3 and the nocturnal AHI 35; in Patient 3, the diurnal AHI after 1 month was 13 and the nocturnal AHI 59.

Figure 1. Results of 24-Hour Cardiorespiratory Monitoring and Chemosensitivity to Carbon Dioxide in Patient 1.

One month after the initiation of ticagrelor, Patient 1 had evidence of Cheyne–Stokes respiration (Panel A [top]). Diurnal and nocturnal scores on the apnea–hypopnea index (AHI, the number of occurrences of apnea or hypopnea per hour) are shown. The patient also had increased chemosensitivity to carbon dioxide while receiving ticagrelor (Panel A, middle and bottom). After discontinuation of the drug, the amelioration of symptoms occurred with progressive disappearance of Cheyne–Stokes respiration (Panels B, top, and C, top) and a reduction in chemoreflex sensitivity to hypercapnia (Panels B, middle and bottom, and C, middle and bottom). AU denotes arbitrary units, HCVR hypercapnic ventilatory response, PetCO₂ partial pressure of end-tidal carbon dioxide, and SaO₂ arterial oxygen saturation.
The P2Y12 receptor is expressed not only in platelets but also in other hematopoietic and nonhematopoietic cells, including microglia in the central nervous system, with potential purinergic stimulation of the chemoreflex system. This stimulation may elicit Cheyne–Stokes respiration. In a patient who receives ticagrelor and has persistent dyspnea, screening for Cheyne–Stokes respiration may be considered to address the patient’s discomfort.

Alberto Giannoni, M.D., Ph.D.
Fondazione Toscana Gabriele Monasterio
Pisa, Italy
alberto.giannoni@gmail.com

Michele Emdin, M.D., Ph.D.
Claudio Passino, M.D.
Scuola Superiore Sant’Anna
Pisa, Italy

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.


DOI: 10.1056/NEJMc1601662
Correspondence Copyright © 2016 Massachusetts Medical Society.

NOTICES

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere.

Letters accepted for publication will appear in print, on our website at NEJM.org, or both.

Please note the following:
• Letters in reference to a Journal article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article.
• Letters not related to a Journal article must not exceed 400 words.
• A letter can have no more than five references and one figure or table.
• A letter can be signed by no more than three authors.
• Financial associations or other possible conflicts of interest must be disclosed. Disclosures will be published with the letters. (For authors of Journal articles who are responding to letters, we will only publish new relevant relationships that have developed since publication of the article.)
• Include your full mailing address, telephone number, fax number, and e-mail address with your letter.
• All letters must be submitted at authors.NEJM.org.

Letters that do not adhere to these instructions will not be considered. We will notify you when we have made a decision about possible publication. Letters regarding a recent Journal article may be shared with the authors of that article. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the Journal’s various print and electronic publications and in collections, revisions, and any other form or medium.

NOTICES

Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received.

1ST DUBAI SHOULDER COURSE

The course will be offered in Dubai, Sept. 22–24. It is sponsored by Emirates Orthopaedic Society.

Contact InfoPlus Events, Suite 1406, Lake Central Building, Al Abraj Street, Burj Khalifa Community, P.O. Box 71108, Dubai, United Arab Emirates; or call (971) 4 4218996; or e-mail DubaiShoulder@InfoPlusEvents.com; or see http://www.dubaishoulder.com.

36TH ANNUAL SQUAW VALLEY RETINAL SYMPOSIUM

The conference will be held in Lake Tahoe, CA, Feb. 2–5.

Contact Dr. Robert Wendel or Laura Wendel, 3939 J St., Suite 106, Sacramento, CA 95819; or call (916) 483-6299; or fax (916) 483-6297; or e-mail squawvalleyretina@comcast.net; or see http://www.squawvalleyretina.com.

MINDFUL PRACTICE: ENHANCING QUALITY OF CARE, QUALITY OF CARING, AND RESILIENCE

The workshop will be held in Batavia, NY, Oct. 26–29. It is sponsored by Mindful Practice Programs, Department of Family Medicine, University of Rochester Medical Center.

Contact Mindful Practice Programs, 1381 South Ave., Rochester, NY 14620; or call (585) 275-7666; or see http://www.mindfulpractice.urmc.edu.

28TH ANNUAL FALL FOLIAGE CANCER CONFERENCE

The conference will be held in Asheville, NC, Oct. 21 and 22.

Contact Nancy Robinson, Community Cancer Education, 900 Hendersonville Rd., Suite 311, Asheville, NC; or call (828) 277-9706; or e-mail sha@shalex.net; or see http://www.cceinc.org or http://www.charlotteahec.org/fallfoliage.